USA flag logo/image

An Official Website of the United States Government

Canine Studies to Restore Endogenous Insulin

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93688
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK079434
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MITOKINE BIOSCIENCE, LLC
MITOKINE BIOSCIENCE, LLC PO Box 275 HANCOCK, ME 04640
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Canine Studies to Restore Endogenous Insulin
Agency: HHS
Contract: 1R43DK079434-01A2
Award Amount: $277,416.00
 

Abstract:

DESCRIPTION (provided by applicant): Identifying a safe, oral treatment capable of both restoring the natural mechanisms that regenerate pancreatic beta cells and improving function would be a major advance in therapeutic options for diabetes. The objecti ve of the proposed research is to test the hypothesis that oral administration of a natural beta cell product, that has been depleted by the disease, will result in improved beta cell function as measured by Cpeptide, fasting glucose, glycosylated hemoglo bin and fructosamine. Twelve companion dogs that are naturally insulin-dependent will be studied in collaboration with the Clinical Sciences Department at Purdue University School of Veterinary Medicine. The aims of this research are 1) to test the feasi bility and safety of this new diabetes therapy by measuring glycemic control before and after treatment and 2) test the pharmacokinetics of the treatment at various dosages. The long-term goal is to provide an oral product for both veterinary and human dia betes that offers sustained resolution of blood glucose abnormalities by restoring endogenous insulin without side effects or toxicity. PUBLIC HEALTH RELEVANCE: The proposed research will test the hypothesis that restoring a natural product of the cell s that make insulin will improve their function and the symptoms of diabetes. The project will assess whether this treatment offers sustained improvement in glucose control without side effects or toxicity. If proven safe and effective, this treatment coul d be a major advance forward in therapeutic interventions for both type 1 and type 2 diabetes.

Principal Investigator:

B. B. Ligon
2074226838
BLIGON@MITOKINE.COM

Business Contact:

B. B. Ligon
bligon@mitokine.com
Small Business Information at Submission:

MITOKINE BIOSCIENCE, LLC
MITOKINE BIOSCIENCE, LLC PO Box 275 HANCOCK, ME 04640

EIN/Tax ID: 114196788
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No